Skip to main content Skip to footer

Orexo press releases

Notice of Annual General Meeting of Orexo

7 March 2017 at 10:00 – RegulatoryGeneral Meeting

Notice of Annual General Meeting of Orexo

Orexo Completes Bond Buyback Program

20 February 2017 at 08:00

Orexo Completes Bond Buyback Program

Number of shares and votes in Orexo

31 January 2017 at 17:45 – Regulatory

Number of shares and votes in Orexo

Full Year Report 2016

26 January 2017 at 08:00 – RegulatoryReportQ4

Full Year Report 2016

Orexo Completes Bond Buyback Program

21 December 2016 at 08:00

Orexo Completes Bond Buyback Program

Orexo appeal Zubsolv® US district court decision

8 December 2016 at 08:00 – Regulatory

Orexo appeal Zubsolv® US district court decision

Number of shares and votes in Orexo

31 October 2016 at 18:00 – Regulatory

Number of shares and votes in Orexo

Interim Report January-September 2016

20 October 2016 at 08:00 – RegulatoryReportQ3

Interim Report January-September 2016

FDA Approves Unique Low Dosage of Zubsolv®

6 October 2016 at 08:00 – Regulatory

FDA Approves Unique Low Dosage of Zubsolv®

Number of shares and votes in Orexo

30 September 2016 at 18:00 – Regulatory

Number of shares and votes in Orexo

Issue and repurchase of class C shares

22 September 2016 at 18:00

Issue and repurchase of class C shares

Interim Report January-June 2016

12 July 2016 at 08:00 – RegulatoryReportQ2

Interim Report January-June 2016

Interim Report January-March 2016

21 April 2016 at 08:00 – RegulatoryReportQ1

Interim Report January-March 2016

Report from Orexo AB’s Annual General Meeting, 15 April 2016

15 April 2016 at 19:30 – RegulatoryGeneral Meeting

Report from Orexo AB’s Annual General Meeting, 15 April 2016

Orexo’s Annual Report for 2015 released

22 March 2016 at 11:45 – RegulatoryReport

Orexo’s Annual Report for 2015 released

IR & Corporate Communications Director

Lena Wange

Subscribe